Drug intelligence / Profile preview

HRS-4508

Development stage: Phase 2
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HRS-4508 is an oral, efficient, and selective tyrosine kinase inhibitor developed by Jiangsu Hengrui Pharmaceuticals for the treatment of advanced or metastatic solid tumors. Its anti-tumor effect is achieved by inhibiting tumor cell proliferation through selective inhibition of tyrosine kinases. The drug is currently in Phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and to determine the recommended dose for further studies.

Targets

Tyrosine kinase

Beyond the preview

Go deeper on HRS-4508.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-4508.

Explore the full profile